ALTEOGEN Inc (196170) - Net Assets

Latest as of March 2026: ₩512.86 Billion KRW ≈ $347.56 Million USD

Based on the latest financial reports, ALTEOGEN Inc (196170) has net assets worth ₩512.86 Billion KRW (≈ $347.56 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩729.47 Billion ≈ $494.35 Million USD) and total liabilities (₩216.61 Billion ≈ $146.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALTEOGEN Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩512.86 Billion
% of Total Assets 70.31%
Annual Growth Rate 25.98%
5-Year Change 232.36%
10-Year Change 904.77%
Growth Volatility 35.83

ALTEOGEN Inc - Net Assets Trend (2014–2025)

This chart illustrates how ALTEOGEN Inc's net assets have evolved over time, based on quarterly financial data. See ALTEOGEN Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for ALTEOGEN Inc (2014–2025)

The table below shows the annual net assets of ALTEOGEN Inc from 2014 to 2025. For live valuation and market cap data, see 196170 market cap.

Year Net Assets Change
2025-12-31 ₩454.44 Billion
≈ $307.97 Million		 +65.80%
2024-12-31 ₩274.09 Billion
≈ $185.75 Million		 +85.39%
2023-12-31 ₩147.84 Billion
≈ $100.19 Million		 -0.62%
2022-12-31 ₩148.76 Billion
≈ $100.81 Million		 +8.80%
2021-12-31 ₩136.73 Billion
≈ $92.66 Million		 +4.25%
2020-12-31 ₩131.16 Billion
≈ $88.89 Million		 +87.42%
2019-12-31 ₩69.98 Billion
≈ $47.43 Million		 +5.04%
2018-12-31 ₩66.63 Billion
≈ $45.15 Million		 +67.21%
2017-12-31 ₩39.85 Billion
≈ $27.00 Million		 -11.90%
2016-12-31 ₩45.23 Billion
≈ $30.65 Million		 +17.32%
2015-12-31 ₩38.55 Billion
≈ $26.13 Million		 +7.61%
2014-12-31 ₩35.82 Billion
≈ $24.28 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to ALTEOGEN Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 16526.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings ₩218.54 Billion 49.09%
Other Components ₩226.66 Billion 50.91%
Total Equity ₩445.19 Billion 100.00%

ALTEOGEN Inc Competitors by Market Cap

The table below lists competitors of ALTEOGEN Inc ranked by their market capitalization.

Company Market Cap
Smith & Nephew SNATS Inc
NYSE:SNN
 $12.78 Billion
Meritz Financi
KO:138040
 $12.79 Billion
Far EasTone Telecommunications Co Ltd
TW:4904
 $12.79 Billion
Lynas Rare EARTHS Ltd
AU:LYC
 $12.80 Billion
Gfl Environmental Holdings Inc
TO:GFL
 $12.77 Billion
BridgeBio Pharma Inc
NASDAQ:BBIO
 $12.77 Billion
COLOPLAST SP.ADR 1/10 DK1
F:CBH
 $12.73 Billion
Logitech International S.A.
SW:LOGN
 $12.73 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ALTEOGEN Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 273,593,211,290 to 445,194,059,000, a change of 171,600,847,710 (62.7%).
  • Net income of 141,666,024,710 contributed positively to equity growth.
  • Share repurchases of 1,366,110,000 reduced equity.
  • New share issuances of 162,428,287,850 increased equity.
  • Other factors decreased equity by 131,127,354,850.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₩141.67 Billion +31.82%
Share Repurchases ₩1.37 Billion -0.31%
Share Issuances ₩162.43 Billion +36.48%
Other Changes ₩-131.13 Billion -29.45%
Total Change ₩- 62.72%

Book Value vs Market Value Analysis

This analysis compares ALTEOGEN Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 42.35x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 290.98x to 42.35x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩1211.42 ₩352500.00 x
2017-12-31 ₩1053.24 ₩352500.00 x
2018-12-31 ₩1756.56 ₩352500.00 x
2019-12-31 ₩1678.64 ₩352500.00 x
2020-12-31 ₩3113.74 ₩352500.00 x
2021-12-31 ₩3232.11 ₩352500.00 x
2022-12-31 ₩2888.81 ₩352500.00 x
2023-12-31 ₩2862.27 ₩352500.00 x
2024-12-31 ₩5133.55 ₩352500.00 x
2025-12-31 ₩8324.17 ₩352500.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ALTEOGEN Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 31.82%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 65.63%
  • • Asset Turnover: 0.31x
  • • Equity Multiplier: 1.57x
  • Recent ROE (31.82%) is above the historical average (1.52%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 2.60% 13.22% 0.19x 1.06x ₩-2.65 Billion
2015 3.13% 25.57% 0.12x 1.02x ₩-2.65 Billion
2016 -7.93% -52.42% 0.14x 1.06x ₩-8.11 Billion
2017 -18.69% -61.54% 0.28x 1.08x ₩-11.43 Billion
2018 -10.31% -50.15% 0.19x 1.07x ₩-13.53 Billion
2019 -1.01% -2.41% 0.34x 1.23x ₩-7.70 Billion
2020 -0.74% -2.29% 0.27x 1.21x ₩-14.09 Billion
2021 4.39% 14.59% 0.16x 1.90x ₩-7.67 Billion
2022 -5.48% -28.28% 0.12x 1.65x ₩-23.02 Billion
2023 -2.28% -3.49% 0.38x 1.73x ₩-18.18 Billion
2024 22.75% 60.52% 0.25x 1.49x ₩34.89 Billion
2025 31.82% 65.63% 0.31x 1.57x ₩97.15 Billion

Industry Comparison

This section compares ALTEOGEN Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $328,962,346,017
  • Average return on equity (ROE) among peers: -14.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ALTEOGEN Inc (196170) ₩512.86 Billion 2.60% 0.42x $12.78 Billion
ORIENTBIO Inc. (002630) $67.35 Billion -2.60% 1.21x $76.42 Million
Green Cross (005250) $1.45 Trillion 1.27% 0.81x $355.67 Million
Green Cross Holdings Preference Shares (005257) $1.44 Trillion 3.01% 0.78x $3.44 Million
Pharmicell (005690) $55.99 Billion -70.00% 0.14x $594.51 Million
GeneOne Life Science Inc (011000) $111.49 Billion -69.75% 0.35x $54.38 Million
HLB Co. Ltd (028300) $19.44 Billion 0.00% 0.66x $4.30 Billion
Daesung Microbiological Labs. Co. Ltd (036480) $25.09 Billion 18.13% 0.29x $16.56 Million
Seoulin Bioscience Co.Ltd (038070) $83.06 Billion -0.14% 0.37x $30.57 Million
Hyundai Bioscience Co. Ltd (048410) $22.49 Billion -13.82% 0.46x $622.85 Million
iNtRON Biotechnology Inc (048530) $11.93 Billion -9.93% 0.65x $57.85 Million

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$12.78 Billion
₩18.85 Trillion KRW
Market Cap Rank
#1874 Global
#46 in Korea
Share Price
₩352500.00
Change (1 day)
+1.00%
52-Week Range
₩289500.00 - ₩559000.00
All Time High
₩559000.00
Categories
Companies in Korea Biotechnology
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more